Introduction

Ganoderma lucidum, widely known as Lingzhi or Reishi, has a longstanding history in traditional Asian medicine and is now a popular ingredient in global nutraceuticals and functional foods. With the rise in consumer demand for natural health products, the United States has seen a surge in imports and commercialization of Ganoderma-derived products. However, successful entry into the U.S. market requires a thorough understanding of the regulatory landscape—particularly the FDA and the Generally Recognized as Safe (GRAS) system. This article comprehensively explores the ingredient status of Ganoderma extract, Ganoderma lucidum extract, Lingzhi extract, and Reishi mushroom extract under the FDA and GRAS framework, outlining compliance strategies for manufacturers and exporters.

1. The U.S. Regulatory System for Dietary Ingredients

The U.S. regulatory structure for foods and dietary supplements is overseen by the Food and Drug Administration (FDA). The primary laws affecting botanicals like Ganoderma include:

• The Federal Food, Drug, and Cosmetic Act (FD&C Act)

• The Dietary Supplement Health and Education Act of 1994 (DSHEA)

• The GRAS Notification Program

Products containing Ganoderma extracts can be regulated as conventional foods, dietary supplements, or even as food additives, depending on their intended use, claims, and form.

2. GRAS Status and its Significance

a) What is GRAS?
“Generally Recognized as Safe” (GRAS) is a regulatory classification in the U.S. allowing certain food ingredients to be marketed without premarket FDA approval if they are generally recognized, by qualified experts, as safe under the conditions of their intended use.
GRAS status can be achieved either through a self-affirmation process or a formal notification to the FDA.
The safety evidence must be published and available in the scientific literature, or based on a long history of safe use in food.
b) Pathways to GRAS Status for Ganoderma Extracts

• Self-Affirmed GRAS: A company may assemble its own panel of experts to review all safety and toxicology data for Ganoderma extract or related ingredients. If affirmed, the ingredient can be used without FDA notification, although some companies voluntarily submit a GRAS Notice for added credibility.

• FDA-Notified GRAS: Submission of a GRAS Notice to the FDA, including all supporting safety data, is reviewed by the agency. If accepted, the FDA issues a “no questions” letter.

c) Challenges for Ganoderma Extract
To date, Ganoderma lucidum extract is not listed on the FDA’s published GRAS Notices database, meaning most products rely on self-affirmed GRAS status or classification as dietary supplements.
For use in conventional foods or beverages, a robust safety dossier is required, including toxicological studies and evidence of traditional use.

3. Ganoderma Extracts as Dietary Supplement Ingredients

a) New Dietary Ingredient (NDI) Notification
Under DSHEA, if Ganoderma extract, Lingzhi extract, or any new form of Reishi mushroom extract was not marketed as a dietary ingredient in the U.S. before October 15, 1994, a New Dietary Ingredient (NDI) notification must be filed with the FDA at least 75 days prior to marketing.
The notification must include product identity, manufacturing process, specifications, and a comprehensive safety review.
b) Existing Use and Market History
If substantial evidence exists that Ganoderma lucidum extract has been in use in the U.S. supplement market prior to 1994, it may qualify as an “old dietary ingredient,” exempting it from the NDI notification.
However, new extract types, concentrations, or applications may still require a fresh NDI submission.
c) Labeling and Claims
All Ganoderma extract dietary supplements must adhere to strict labeling requirements, including ingredient listing, suggested use, manufacturer/distributor information, and FDA disclaimer language.
Only structure/function claims (e.g., “supports immune health”) are allowed, and products may not claim to diagnose, treat, cure, or prevent any disease.

4. Food Additive Status and Food Applications

If Ganoderma extract is used in foods other than dietary supplements, it is regulated as a food additive unless it qualifies for GRAS status.

• Food additives require premarket FDA approval through a Food Additive Petition (FAP), a lengthy and expensive process, unless the ingredient qualifies as GRAS.

• For beverage and mainstream food use, manufacturers are encouraged to either self-affirm GRAS or submit a formal GRAS Notice.

5. Safety, Quality, and Documentation Requirements

a) Safety Data

• Toxicological assessments: Acute, sub-chronic, and chronic toxicity studies, allergenicity, and genotoxicity data.

• Human studies: Where available, clinical studies supporting safety and traditional consumption are valuable.

b) Quality Standards

• Specifications for Ganoderma extract (e.g., bioactive marker content, purity, absence of contaminants) must be established and documented.

• Good Manufacturing Practice (GMP) compliance is mandatory for dietary supplements.

c) Traceability and Records

• Maintain documentation on sourcing, manufacturing, testing, and expert panel deliberations (for GRAS self-affirmation).

6. Enforcement and Post-Market Considerations

• The FDA monitors the dietary supplement and food market for compliance with safety, labeling, and claims regulations.

• Products may be subject to warning letters, recalls, or import alerts if found non-compliant.

• Adverse event reporting is mandatory for dietary supplements under the Dietary Supplement and Nonprescription Drug Consumer Protection Act.

7. Recent Trends and Market Insights

• Increased interest in functional mushrooms has led to more rigorous scrutiny by the FDA.

• Third-party certifications (NSF, USP, Non-GMO, Organic) can support market credibility.

• Science-based marketing and transparent safety documentation are essential to avoid regulatory challenges.

Conclusion

Successfully marketing Ganoderma extract, Ganoderma lucidum extract, Lingzhi extract, and Reishi mushroom extract in the U.S. food and dietary supplement industry demands deep knowledge of the FDA’s regulatory framework, GRAS requirements, and NDI notification pathways. Companies must invest in robust safety documentation, ensure transparent ingredient labeling, and monitor compliance continuously to maintain market access and brand reputation in this fast-growing segment.

Read More:

Key Considerations for Controlling Residual Solvents and Heavy Metals in Ganoderma Raw Materials

Why Global Wellness Brands Are Seeking Organic Mushroom Powder OEM Partners